The cost of prescription metronidazole vaginal gel 0.75% depends on the actual intravaginal product, package, pharmacy and method of payment. This is not the same item as oral metronidazole or the 0.75% gel formulated for facial skin. A vaginal gel prescription typically identifies an applicator-based product for bacterial vaginosis (BV), and the amount dispensed should correspond to the prescription. The 0.75% vaginal gel guide explains how to recognize the formulation.
An authentic comparison starts with a quote for the prescribed 0.75% vaginal product, not a generic metronidazole search result that merges unrelated dosage forms. Brand and generic labels, packaging with applicators, pharmacy fees and individual insurance benefits can change the patient's out-of-pocket obligation. A general description of FDA approval or an NDC entry is not a claim that a particular pharmacy has the package in stock.
This page addresses the cost drivers of the conventional 0.75% vaginal gel category and Vandazole-related brand questions. The 1.3% single-dose Nuvessa formulation is clinically and commercially different and has its own Nuvessa cost guide. We do not quote current dollar amounts, post coupon codes or recommend swapping concentrations to obtain a lower price.
For this page, the relevant baseline is prescription metronidazole vaginal gel 0.75%. Labels identify the vaginal route and distinguish it from dermatologic metronidazole gels. The package often includes equipment for applying the prescribed amount intravaginally; the specified product and dispensing quantity determine what is being quoted. A skin gel tube with the same numerical concentration is not a comparable pharmacy item.
The distinction also applies within vaginal metronidazole: Nuvessa 1.3% uses a different concentration and labeled single-dose presentation. Neither the lower nor higher percentage is a simple price-per-gram substitute for the other. A clinician determines the indicated product. For route-level identity, see the vaginal gel product hub before requesting quotes.
| Product shown on a pharmacy list | Relevant price comparison | What cannot be inferred |
|---|---|---|
| Generic vaginal gel 0.75% | Exact intravaginal product, package and applicators | Equivalence with facial skin gel of the same percentage |
| Vandazole 0.75% | Brand package versus authorized generic choices | Brand stock from a historical label listing |
| Nuvessa or generic vaginal gel 1.3% | Separate product and plan claim | That a 1.3% single-dose package replaces the 0.75% regimen |
| Topical rosacea gel 0.75% | Not part of vaginal gel pricing | That identical percentages imply identical administration |
Vaginal prescription gels are billed and dispensed in defined tube, carton or applicator presentations. An advertisement for a container size that does not match the prescription may understate the actual amount needed for the prescribed course. Ask the pharmacist whether the full package and applicable administration supplies are included in the quote, rather than relying on a per-gram figure from a general listing.
Package presentation can vary across manufacturers and over time. A generic label describing an approved product does not confirm a pharmacy's available package today. Comparing the same route, 0.75% concentration, quantity and dispensing arrangement reduces confusion between apparently cheap and expensive listings.
Vandazole is a branded 0.75% vaginal metronidazole gel, while approved generic 0.75% vaginal products may appear under manufacturer names. Being 'generic metronidazole' is not enough to prove that every listing is an approved or substitutable match for the particular branded product. The pharmacist should verify the actual dosage form, concentration, approved status and applicable state substitution rules.
If the prescription says Vandazole, ask whether it requires a branded package or permits an appropriate generic. Some pharmacy systems can quote both, but the listed brand may not be available to dispense. The Vandazole price comparison concentrates on this branded-versus-generic decision without extending it to Nuvessa 1.3%.
Prescription coverage may depend on whether the prescribed product is on the formulary, whether the pharmacy is in-network and what patient cost sharing applies. A brand-name vaginal gel and a generic formulation can fall into different benefit categories. Prior authorization should be checked rather than presumed, and any claim rejection should be explained in terms of the individual plan's rules.
Request a quote for the exact vaginal product. If the brand is excluded or a different product is preferred, a pharmacist and prescriber should interpret whether the suggested alternative is appropriate. Coverage policy cannot be used to justify replacing a vaginal metronidazole formulation with an oral or dermatologic one without clinical assessment.
For uninsured patients, an apples-to-apples comparison means two licensed pharmacies quoting the complete prescribed 0.75% vaginal gel package. Ask for the brand or labeler, concentration, quantity, applicators and all fees. If a third-party discount card is offered, have the pharmacy confirm that it covers this vaginal product rather than just oral generic tablets.
A cash quote is not proof of stock; confirm when the pharmacy can obtain and dispense the item. If delivery is offered, check shipping costs and handling rules. The vaginal online-pharmacy checklist covers legitimacy and product descriptions, whereas this page focuses on making price quotes comparable.
A lower quote for 0.75% vaginal gel does not establish that it should replace a prescribed 1.3% single-dose gel, and a cheaper oral tablet is not an equivalent vaginal route. Different products have different labeled instructions and treatment contexts. Cost discussions should happen after the medical decision, with any proposed change referred to the prescriber.
The CDC recognizes multiple treatments for bacterial vaginosis, but clinical options are not a consumer-designed exchange chart. A person with new symptoms also should not assume that a past BV prescription applies to the current problem. The vaginal prescription guide explains why diagnosis and product selection come before purchasing.
The pharmacy may need to order a particular vaginal gel package or clarify whether another approved 0.75% product can be dispensed under the prescription. Ask whether the issue is a missing branded package, a wholesaler delay, or a formulation mismatch. These possibilities require different responses and cannot be resolved from an NDC listing alone.
If an alternative is suggested, verify the exact route, dosage form and concentration. Clinician approval may be necessary for a different medicine or different regimen. The vaginal gel availability guide provides further checks without claiming live pharmacy stock.
Ask the pharmacy to identify the complete product and brand or generic status, confirm the concentration, package and applicators, and specify whether the quoted amount reflects insurance, ordinary cash or a discount program. Check for extra fees and whether the prescription can be filled in the required timeframe. A reliable comparison uses the same medicine and quantity throughout.
At pickup, read the label carefully. It should identify a product intended for vaginal use, not a skin gel. Ask a pharmacist about any unfamiliar carton or proposed substitute before use. A website cannot assess an individual BV treatment or validate a particular patient's benefit; its role is to clarify what should be checked.
No. They have different intended routes and product labeling, even when a concentration number is the same.
No permanent price relationship can be guaranteed. Brand availability, approved generic selection, package and payment method affect any actual quote.
Ask the dispensing pharmacy to confirm the complete prescribed package and supplied administration equipment.
It may, depending on the plan, formulary and exact product. Verify the patient-specific pharmacy claim and any restrictions.
No. The strengths and labeled presentations differ. They must not be exchanged on the basis of price.
Do not assume so. Discounts are product- and pharmacy-specific and must match the vaginal prescription.
No. Regulatory listing does not establish real-time local inventory.
Patients with valid prescriptions can request cash quotes from licensed pharmacies; the total needs to be confirmed for the exact package.
A pharmacist must evaluate approval and substitution rules against the actual order; patients should not switch products independently.
Discuss the plan restriction with the prescriber and pharmacist. Another treatment may require a new clinical decision and prescription.